A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.
Michael J PishvaianRebecca S SlackWei JiangA Ruth HeJimmy J HwangAmy HankinKaren Dorsch-VogelDivyesh KukadiyaLouis M WeinerJohn L MarshallJonathan R BrodyPublished in: Cancer (2018)
In this heavily pretreated mCRC population, a combination of veliparib and temozolomide was well tolerated with temozolomide doses up to 200 mg/m2 /d, and it was clinically active. PARP inhibitor-based therapy merits further exploration in patients with mCRC. Cancer 2018;124:2337-46. © 2018 American Cancer Society.